In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT

Sylvestor A. Moses, M. Ahad Ali, Song Zuohe, Lei Du-Cuny, Li Zhou Li, Robert Lemos, Nathan Ihle, A. Geoffrey Skillman, Shuxing Zhang, Eugene A Mash, Garth Powis, Emmanuelle Meuillet

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl) benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties.

Original languageEnglish (US)
Pages (from-to)5073-5081
Number of pages9
JournalCancer Research
Volume69
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Proto-Oncogene Proteins c-akt
Pancreatic Neoplasms
Phosphatidylinositol 3-Kinase
Surface Plasmon Resonance
Heterografts
In Vitro Techniques
Pleckstrin Homology Domains
Neoplasms
Spectrum Analysis
Software
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. / Moses, Sylvestor A.; Ali, M. Ahad; Zuohe, Song; Du-Cuny, Lei; Li, Li Zhou; Lemos, Robert; Ihle, Nathan; Skillman, A. Geoffrey; Zhang, Shuxing; Mash, Eugene A; Powis, Garth; Meuillet, Emmanuelle.

In: Cancer Research, Vol. 69, No. 12, 15.06.2009, p. 5073-5081.

Research output: Contribution to journalArticle

Moses, SA, Ali, MA, Zuohe, S, Du-Cuny, L, Li, LZ, Lemos, R, Ihle, N, Skillman, AG, Zhang, S, Mash, EA, Powis, G & Meuillet, E 2009, 'In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT', Cancer Research, vol. 69, no. 12, pp. 5073-5081. https://doi.org/10.1158/0008-5472.CAN-08-3839
Moses, Sylvestor A. ; Ali, M. Ahad ; Zuohe, Song ; Du-Cuny, Lei ; Li, Li Zhou ; Lemos, Robert ; Ihle, Nathan ; Skillman, A. Geoffrey ; Zhang, Shuxing ; Mash, Eugene A ; Powis, Garth ; Meuillet, Emmanuelle. / In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. In: Cancer Research. 2009 ; Vol. 69, No. 12. pp. 5073-5081.
@article{a7019b94775e457bb272390fd7f760f5,
title = "In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT",
abstract = "The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl) benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties.",
author = "Moses, {Sylvestor A.} and Ali, {M. Ahad} and Song Zuohe and Lei Du-Cuny and Li, {Li Zhou} and Robert Lemos and Nathan Ihle and Skillman, {A. Geoffrey} and Shuxing Zhang and Mash, {Eugene A} and Garth Powis and Emmanuelle Meuillet",
year = "2009",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-08-3839",
language = "English (US)",
volume = "69",
pages = "5073--5081",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT

AU - Moses, Sylvestor A.

AU - Ali, M. Ahad

AU - Zuohe, Song

AU - Du-Cuny, Lei

AU - Li, Li Zhou

AU - Lemos, Robert

AU - Ihle, Nathan

AU - Skillman, A. Geoffrey

AU - Zhang, Shuxing

AU - Mash, Eugene A

AU - Powis, Garth

AU - Meuillet, Emmanuelle

PY - 2009/6/15

Y1 - 2009/6/15

N2 - The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl) benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties.

AB - The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl) benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties.

UR - http://www.scopus.com/inward/record.url?scp=67449161813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449161813&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3839

DO - 10.1158/0008-5472.CAN-08-3839

M3 - Article

C2 - 19491272

AN - SCOPUS:67449161813

VL - 69

SP - 5073

EP - 5081

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -